217 results
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
Medicines Agency (EMA) PRIority MEdicines (PRIME) scheme and EMA accelerated assessment; Promising Innovative Medicine designation by the UK Medicines
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
), the conventional assessment of physical function in activities of daily living for patients, not being met. The parties are committed to sharing the full efficacy … treatment development
Develop innovative treatments to eliminate cancer death in children
3 assets undergoing pre-clinical assessment
1 asset
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
the FDIC’s definition of a large or highly complex institution for deposit insurance assessment purposes.
Dollar Amounts in Thousands
RCON
Amount
Assets
1 … assessment purposes.
7. Trading assets
8. Lease financing receivables (net of unearned income)
9. Total assets (4)
Liabilities
10. Interest-bearing
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
are incorporated herein by reference. Such consolidated financial statements and management’s assessment of the effectiveness of internal control over
F-3ASR
EX-4.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
court to require such an undertaking or to make such an assessment in any suit instituted by the Company or the Trustee.
SECTION 515. Waiver of Stay … Jurisdiction, except that no Additional Amounts will be payable for or on account of:
(A) any tax, duty, assessment or other governmental charge which would
6-K
EX-99.1
go1dmmdj
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
6-K
EX-99.1
xvyte6k
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
0wq1nx737 bc5e0u9n
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
c114m24 ti
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
cn3r4zinkhracm8ob32q
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.2
s786 jng0
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
31th5tdpj2 p8287
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
239sax7kmws
24 Jul 23
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
12:43pm
6-K
EX-99.2
thqcpr3btw4r4
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
zizcy 3m6jlxuyg7e
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
xuk89dx05c
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
kma7 qtnpq
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
8mrgbqas6f6sey
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
0w3dtztoq5qt oovo40n
21 Nov 22
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
10:05am
6-K
EX-99.1
h7hkmh
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm